Can alcohol control policies reduce cirrhosis mortality? An interrupted time-series analysis in Lithuania

  • Alexander Tran
  • Huan Jiang
  • Shannon Lange
  • Jakob Manthey
  • Mindaugas Štelemėkas
  • Robertas Badaras
  • Janina Petkevičienė
  • Ričardas Radišauskas
  • Robin Room
  • Jürgen Rehm

Abstract

BACKGROUND AND AIMS: The relationship between alcohol consumption and cirrhosis is well established. Policies that can influence population-level use of alcohol should, in turn, impact cirrhosis. We examined the effect of population-level alcohol control policies on cirrhosis mortality rates in Lithuania - a high-income European Union country with high levels of alcohol consumption.

METHODS: Age-standardized, monthly liver mortality data (deaths per 100,000 adults, aged 15+) from Lithuania were analysed from 2001 to 2018 (n = 216 months) while controlling for economic confounders (gross domestic product and inflation). An interrupted time-series analysis was conducted to estimate the effect of three alcohol control policies implemented in 2008, 2017 and 2018 and the number of cirrhosis deaths averted.

RESULTS: There was a significant effect of the 2008 (P < .0001) and 2017 (P = .0003) alcohol control policies but a null effect of the 2018 policy (P = .40). Following the 2008 policy, the cirrhosis mortality rate dropped from 4.93 to 3.41 (95% CI: 3.02-3.80) deaths per 100,000 adults, which equated to 493 deaths averted. Further, we found that following the 2017 policy, the mortality rate dropped from 2.85 to 2.01 (95% CI: 1.50-2.52) deaths per 100,000 adults, corresponding to 245 deaths averted.

CONCLUSIONS: Our findings support the hypothesis that alcohol control policies can have a significant, immediate effect on cirrhosis mortality. These policy measures are cost-effective and aid in reducing the burden of liver disease.

Bibliographical data

Original languageEnglish
ISSN1478-3223
DOIs
Publication statusPublished - 04.2022

Comment Deanary

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PubMed 35023617